Cabaletta Bio (CABA) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
Cabaletta Bio insider trading at a glance (Oct 9, 2026): in the past 12 months, 7 insiders bought $286K and 0 sold $0 of CABA stock on the open market, including a cluster buy that began Jan 21, 2026.
Get emailed when insiders cluster-buy stocks like CABA
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CABA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | $296K | 8 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 7 Cabaletta Bio, Inc. insiders reported open-market purchases totaling $286K, while 0 insiders reported sales totaling $0. The most recent cluster buy began on Jan 21, 2026, when 7 insiders bought a combined $286K.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jan 21SEC | Steven NichtbergerCEO, President | Buy | 45,0001,031,483 held (+5%) | $2.24 | $101K | -13.8% | — |
| Jan 21SEC | Steve GavelChief Commercial Officer | Buy | 22,170new position | $2.27 | $50K | -15.0% | — |
| Jan 21SEC | Shawn TomaselloDirector | Buy | 22,725new position | $2.21 | $50K | -12.7% | — |
| Jan 21SEC | Mark SimonDirector | Buy | 11,061147,205 held (+8%) | $2.28 | $25K | -15.4% | — |
| Jan 21SEC | Gwendolyn BinderPresident | Buy | 11,31231,312 held (+57%) | $2.19 | $25K | -11.9% | — |
| Jan 21SEC | David J. ChangChief Medical Officer | Buy | 8,800new position | $2.26 | $20K | -14.6% | — |
| Jan 21SEC | Michael GerardGeneral Counsel | Buy | 6,600new position | $2.27 | $15K | -15.0% | — |
| Jan 21SEC | Catherine BollardDirector | Buy | 4,4055,405 held (+440%) | $2.27 | $10K | -15.0% | — |
Insiders at Cabaletta Bio, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Steven NichtbergerCEO, President | $101K | — | Jan 21, 2026 | — |
| Steve GavelChief Commercial Officer | $50K | — | Jan 21, 2026 | — |
| Shawn TomaselloDirector | $50K | — | Jan 21, 2026 | — |
| Mark SimonDirector | $25K | — | Jan 21, 2026 | — |
| Gwendolyn BinderPresident | $25K | — | Jan 21, 2026 | — |
| David J. ChangChief Medical Officer | $20K | — | Jan 21, 2026 | — |
| Michael GerardGeneral Counsel | $15K | — | Jan 21, 2026 | — |
| Catherine BollardDirector | $10K | — | Jan 21, 2026 | — |
CABA stock: common questions
Are Cabaletta Bio, Inc. insiders buying CABA stock?
In the past 12 months, 7 insiders reported open-market purchases of CABA worth $286K. The latest was CEO, President Steven Nichtberger bought $101K of CABA at $2.24 — first open-market purchase in our records.
Are Cabaletta Bio, Inc. insiders selling CABA stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CABA's 52-week range?
Over the past year CABA has traded between $1.89 and $4.15. It last closed at $1.93 on Oct 9, 2026.